How Kisqali Works Against Breast Cancer
Kisqali (ribociclib) treats hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer, typically in advanced or metastatic stages, by blocking proteins that drive cancer cell growth.[1] It targets cyclin-dependent kinases 4 and 6 (CDK4/6), enzymes that help cancer cells divide and proliferate rapidly. By inhibiting these kinases, Kisqali halts the cell cycle at the G1 phase, preventing tumor growth and inducing cancer cell death.[2]
It's used in combination with hormone therapies like an aromatase inhibitor (e.g., letrozole) or fulvestrant, which block estrogen's role in fueling HR+ tumors. This combo disrupts two key pathways—estrogen signaling and CDK4/6 activity—for stronger tumor control than hormone therapy alone.[1][3]
Who Gets Prescribed Kisqali?
Approved for postmenopausal women with HR+/HER2- advanced or metastatic breast cancer as initial endocrine-based therapy. Also for men and pre/perimenopausal women (with ovarian suppression) who progressed on prior endocrine treatment.[1] Not for early-stage breast cancer or other subtypes like triple-negative.[4]
How It's Taken and Treatment Timeline
Patients take Kisqali orally: 600 mg (three 200 mg tablets) once daily for 21 days, followed by 7 days off, in 28-day cycles. Combined with daily letrozole (2.5 mg) or other partners. Treatment continues until disease progression or intolerance; response can last 1-2 years on average in trials.[1][3]
Clinical Trial Results
In the MONALEESA-2 trial, Kisqali plus letrozole extended median progression-free survival to 25.3 months vs. 16 months with letrozole alone. Overall survival improved by about 13 months.[3] MONALEESA-7 showed benefits in premenopausal women.[1] FDA approvals: 2017 (initial), 2018 (expanded), 2022 (first-line with endocrine therapy).[4]
Common Side Effects and Risks
Fatigue, nausea, diarrhea, hair thinning, and low white blood cell counts (neutropenia) affect most patients; neutropenia is managed with dose reductions.[1] Serious risks include infections, lung issues (interstitial lung disease), liver enzyme elevation, and QT prolongation (heart rhythm changes)—requires ECG monitoring.[2] Liver function and blood counts checked regularly.
How Kisqali Compares to Ibrance and Verzenio
All three CDK4/6 inhibitors (Kisqali/ribociclib, Ibrance/palbociclib, Verzenio/abemaciclib) pair with endocrine therapy and show similar progression-free survival gains (20-28 months).[3] Kisqali edges in overall survival data from MONALEESA trials; abemaciclib allows continuous dosing without breaks.[5] Choice depends on side effect profile, insurance, and physician preference.
Cost and Access
Monthly cost exceeds $15,000 without insurance; patient assistance programs from Novartis reduce it for eligible users.[6] Patents on ribociclib extend to 2034 in the US—check DrugPatentWatch.com for expiry details and generics.
[1] Kisqali Prescribing Information, Novartis, 2023.
[2] FDA Label, Kisqali, 2022.
[3] NEJM, MONALEESA-2/7 Trials, 2019/2021.
[4] FDA.gov Approvals Summary.
[5] Lancet Oncology, CDK4/6 Inhibitor Comparisons, 2022.
[6] GoodRx Pricing Data, 2024.